The history and regulatory mechanism of the Hippo pathway

Wantaek Kim1,* & Eek-hoon Jho2, *
1Rare Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KIRIBB), Daejeon 34141, 2Department of Life Science, University of Seoul, Seoul 02505, Korea

INTRODUCTION

Both the growth to the right size and the patterning to an accurate shape are essential for an organ to ensure functionality during development and regeneration. These have been obviously curious topics in biology; however, the mechanism for how organ size is controlled remains poorly understood (1-3). Organ size control is tightly coordinated in controlling organ size and maintaining tissue homeostasis. Given the significance of these processes, the dysregulation of the Hippo pathway has also implicated various diseases, such as tissue degeneration and cancer. By regulating the downstream transcriptional co-activators YAP and TAZ, the Hippo pathway coordinates cell proliferation and apoptosis in response to a variety of signals including cell contact inhibition, polarity, mechanical sensation and soluble factors. Since the core components and their functions of the Hippo pathway are evolutionarily conserved, this pathway serves as a global regulator of organ size control. Therefore, further investigation of the regulatory mechanisms will provide physiological insights to better understand tissue homeostasis. In this review, the historical developments and current understandings of the regulatory mechanism of Hippo signaling pathway are discussed. [BMB Reports 2018; 51(3): 106-118]

*Corresponding authors. Wantaek Kim, Tel: +82-42-860-4385; Fax: +82-42-860-4489; E-mail: wantaekim@kribb.re.kr; Eek-hoon Jho, Tel: +82-2-6490-2671; Fax: +82-2-6490-2664; E-mail: ej70@uos.ac.kr

https://doi.org/10.5483/BMBRep.2018.51.3.022

Received 8 January 2018

Keywords: Development, Hippo pathway, Size control, TAZ, YAP
YAP/TAZ to enter the nucleus to activate the transcriptional programs that are involved in cell proliferation and survival (12, 16). In addition, alternative models have shown that YAP/TAZ activity can be modulated by novel regulators such as deubiquitinase YOD1, MAP4 kinase or spatial organization of core components (17-20). The Hippo pathway has a significant impact on a variety of human diseases including tissue degeneration and cancer. Besides the primary functions of cell proliferation and organ size control, the reports recently published expand our understanding of the Hippo pathway into previously unrecognized cellular processes including miRNA biogenesis, innate immunity, autophagy, atherogenesis, and cell ploidy (21-29). Due to its importance in pathological and physiological contexts, the Hippo pathway has attracted much attention, and the numbers of reports are growing rapidly every year (Fig. 1).

LONG JOURNEY TO ELUCIDATION OF THE HIPPO PATHWAY

Discovery of the core components
In 1995, a mosaic-based screening in a Drosophila imaginal disc to identify genes involved in growth control revealed Warts (Wts), which encodes a kinase of the Nuclear Dbf2-related (NDR) family, as a tumor suppressor gene. The loss of Wts in flies resulted in robust overgrowth in multiple tissues without affecting cell fate determination (30, 31). The development of soft-tissue sarcomas and ovarian tumors in mice-deficient Lats1, a mammalian homologue of Drosophila Wts, further confirmed its tumor suppressive function in mammals (32). Although a cell cycle regulator CDC2 was identified as a binding partner (33), information regarding its regulators, substrates and additional binding partners remained largely unknown for several years since Wts was discovered. The identification of Salvador (Sav) by the two groups led to our interest in a novel growth-regulatory pathway (34, 35). Mutations in Sav, WW45 in humans, which contains two WW-domains, resulted in a similar overgrowth elicited by a mutation in Wts. In particular, Hariharan and colleagues have addressed the physical interaction of Sav with Wts and its function that limits cell proliferation and stimulates apoptosis by regulating Cyclin E and Diap (Drosophila inhibitor of apoptosis) transcriptionally. Supporting its role in tumor suppression, mutation in the human homologue WW45 was observed in cancer cell lines (34). The next substantial advance in the size-control mechanism was the discovery of the Hippo (Hpo) tumor suppressor gene, which encodes Ste-20 family protein kinase and is the homolog of MST1 and MST2 in humans (36-40). Several independent groups have provided the evidence that Hpo genetically and physically interacts with Sav and Wts to restrict cell proliferation and function in a common pathway. Hpo-mediated phosphorylation of Sav with Wts is particularly significant because it provides the signaling module of a new growth-regulatory pathway (Hippo pathway) consisting of kinase cascade. Mats was incorporated as a bona fide regulator of the Hippo pathway. The loss-of-function of Mats causes massive tissue growth, which is similar to the phenotype caused by the loss of Hpo, Sav or Wts. Further investigation revealed that Mats, MOB1 in humans, phosphorylation by Hpo is required for Wts kinase activity (41, 42). Key findings on the Hippo signaling pathway are chronologically summarized in Fig. 2.

Yorkie/YAP as a transcriptional activator in the Hippo pathway
Since the expression of genes such as Cyclin E and Diap could be regulated by the Hippo pathway (36), the identification of the transcriptional regulator(s) that functionally link with upstream kinase cascade was required. In this regard, Huang et al. performed a yeast two hybrid screen with Wts as a bait to search for a transcriptional activator and finally identified Yorkie (Yki), YAP and its parologue TAZ in mammals, as a downstream effector in growth regulation (10). Biochemical and genetic studies revealed that Yki is required for normal tissue growth and its activity is inhibited by Wts-mediated phosphorylation (10). In addition, the removal of Yki in Drosophila diminished the overgrowth phenotype caused by
deleting upstream kinases Wts or Hpo, which indicated that Yki is a central transcription regulator of the Hippo signaling pathway. Guan and colleagues uncovered an underlying molecular mechanism by which Wts/LATS inhibits Yki/YAP activity. They observed YAP contains five LATS kinase consensus sequences (HxRxxS/T) and phosphorylation at S127 leads to cytoplasmic retention of YAP via the interaction with 14-3-3, thereby inhibiting transcriptional activity (43). The central mechanism of the Hippo signal transduction has been established by these remarkable findings and we are currently able to measure the output of the Hippo signaling by easily examining the level of phosphorylation on YAP-S127. In addition, the function of Yki as a critical effector in organ growth as demonstrated in flies was further confirmed in a genetic mouse model. The removal of Yap largely suppressed the phenotypes caused by the deletion of Nf2, a homolog of Drosophila Merlin that is an upstream regulator of Hpo (44). Therefore, growth regulatory function by Hpo-Yki/YAP signaling is evolutionarily conserved in the mechanism of size control. Expecting its growth-promoting capability, YAP was suggested as a potential oncogene due to its association with gene amplification and epigenetic modulation in human cancers, and it is currently accepted as a critical “driver” gene (45-48). Taken together, the Hippo signaling plays a critical role in tumor suppression and its dysregulation is associated with human cancers. Further details about the role of Hippo signaling in different cancers are discussed in an accompanying paper (Kim and Myung, in this issue). The schematic diagram for the components of the Hippo signaling pathway described in this review is displayed in Fig. 3.

![Fig. 2. Timeline of the major advances and discoveries in the Hippo pathway.](image-url)
Role of Yki/YAP in transcriptional activation

Unlike other transcriptional factors, Yki and YAP/TAZ do not have a DNA-binding ability; therefore, they require binding partner(s) that directly bind to DNA and mediate target gene expression. YAP was identified by Sudol as the Yes, tyrosine kinase- associated protein (49). Therefore, before elucidation of its crucial role in organ size control, several DNA binding proteins, including p73, p53BP-2, SMAD7, ERBB4, PEBP2α, RUNX2 and TEAD, had been already reported as YAP-interacting transcriptional factors (50-56). The binding partners of YAP/TAZ are reviewed in detail in an accompanying paper (Kim et al., in this issue). However, the physiological relevance of these interactions in organ size control remains unknown. Multiple lines of evidence revealed that Scalloped (Sd), TEAD1-4 in humans, is the major binding partner of Yki/YaP in regulating gene expression and tissue growth (57-60). The loss of TEAD as well as the TEAD-binding deficient mutant of YAP (S94A or S79A in humans or mice, respectively) can no longer activate target gene expression. Additionally, the knock-in (KI) of this TEAD binding mutant exhibits a similar phenotype as the YAP knockout (KO) in mice tissues (61, 62). The list of the genes induced by YAP generally overlapped with that activated by TEAD or TEAD-VP16 (YAP-binding deficient but a constitutively active form of TEAD via a fusion of VP16 transactivation domain) (57, 60). Recent studies suggested that VGLL4 competes with YAP for binding TEAD and functions as a tumor suppressor (63). Tgi, a similarly functioning protein like VGLL4, was also observed in Drosophila (64). It is not known how YAP/TAZ is translocated into the nucleus and will be interesting to test whether those YAP/TAZ interacting partners are involved in that process.

UPSTREAM SIGNALS OF THE HIPPO PATHWAY

Cell polarity and cell contact

The growth-regulatory pathway from MST1/2 (Hpo) to YAP/TAZ (Yki)-mediated transcription was established almost a decade after the first gene, Wt1, was identified. However, it remains questionable which and how the physiological cues were delivered into the Hippo pathway in regulating organ size. The identification of the apical-basal and planar cell polarity machinery that regulate Hippo signaling initially provided the entry point to understanding these missing links. The FERM domain proteins Merlin (Mer) and Expanded (Ex) have known to co-localize at the adherens junctions to link transmembrane proteins to the cytoskeleton. In addition, the mutation in the Neurofibromatosis type-2 (Nf2), a homolog of Drosophila Merlin, causes a familial cancer syndrome; but, its
downstream mechanism remains elusive. Hamaratoglu et al. clearly demonstrated that Mer and Ex genetically function at the upstream of Hpo kinase and as tumor suppressors (65). Mer and Ex synergistically induce Wts phosphorylation and subsequent Yki inhibition. Moreover, it soon became apparent that atypical cadherin Fat could act at the upstream of Ex by promoting its stability and apical membrane localization (66-68). Also, the Sterile 20-like kinase Tao-1 has been reported as a mediator that connects upstream components Ex and Mer to the Hippo pathway by directly phosphorylating and activating Hpo kinase, which leads to a Wts mediated repression of Yki (69, 70). Recently, it has been reported that Ex is required for apical localization of Schwannomin interacting protein 1 (Schip1) and Schip1 recruits Tao-1 kinase for the phosphorylation of Hpo kinase (71). Another major progress was made by the identification of Kibra (72-74). Kibra forms a complex with Ex and Mer to recruit the core components to the apical junction in the epithelial cell for Hippo signaling activation. Su et al. have further added another mode of regulation which shows that Kibra activates the Hippo pathway together with Mer and Sav, but independent of Ex, at the non-junctural site (medial apical cortex) (75). Crumbs (Crb) was identified as a putative surface receptor linking apical polarity with organ size determination. Interestingly, both overexpression and depletion of Crb induces Yki activity, thereby driving tissue overgrowth; although, it has been reported as a tumor suppressor in human cancer (76-79). In addition to the apical component such as Ex, components of Crb polarity complex, including PALS1, PATJ and AMOT, are also able to strongly interact and induce cytoplasmic retention of YAP/TAZ when cells are in high density (80). These remarkable findings have established cell polarity as an intrinsic upstream signal of the Hippo pathway in controlling organ size and tumorigenesis.

Cell-adhesion molecules are regulators of the Hippo pathway and function as tumor suppressors. α-catenin, an adaptor protein between the membrane and actin cytoskeleton for adherens junction (AJ) formation, was discovered as a molecular linker between the AJ and Hippo pathway (81, 82). Through molecular and genetic analysis of the mouse model, it was reported that α-catenin functions as a tumor suppressor in skin epidermis by preventing nuclear localization and transcriptional activity of YAP (61, 83). A component of cell adhesion junction Echinoid was also identified as a tumor suppressor and upstream modulator of the Hippo pathway. Echinoid physically interacts with and stabilizes Sav, thereby inactivating the Yki activity in Drosophila (84, 85). Thus, cell junction formation exerts as an intrinsic cue to regulate the Hippo signaling. A detailed discussion on the upstream pathways for Hippo signaling in Drosophila organ development is reviewed in an accompanying paper (Choi, in this issue).

Physical signals
Cells are exposed to physical constraints or mechanical cues during organ growth and regeneration and then activate the Hippo pathway to limit tissue overgrowth by restricting cell proliferation and survival. Cell contact inhibition is a well-established growth-inhibitory signal and acts as a determinant of YAP inactivation in the cell culture system as well as in vivo. At high cell density, LATS1/2 kinase are activated and phosphorylates YAP and TAZ at S127 and S89, respectively, which generate a docking site for the 14-3-3 interaction. 14-3-3 retains YAP/TAZ at the cytoplasm and consequently induces their degradation via the β-TrCP E3 ligase-mediated ubiquitin proteasome system. The levels of many Hippo signaling components are controlled by ubiquitin modification. Further discussion on the role of ubiquitin modification in diverse cellular contexts is described in an accompanying paper (Kim and Jho, in this issue). On the other hand, YAP is predominantly present in the nucleus at low cell density, when LATS1/2 kinase activity is low. A physiological relevance to cell density-dependent YAP regulation was further elucidated in the early fate decision of trophectoderm and inner cell mass in mice embryos. YAP primarily localizes in the nuclei of outer cells, whereas outer cells are not fully enclosed by other cells, and it mimics low cell density. Whereas, YAP is phosphorylated and present in the cytoplasm of inner cells that are surrounded by other cells which mimics high cell density. The differential localization patterns of YAP between the inner and outer cells is crucial for cell fate determination (57, 86). In addition to LATS1/2 kinase, the non-receptor tyrosine phosphatase PTPN14 has emerged as a cell-density dependent regulator of YAP regardless of its enzymatic activity. The direct interaction of PTPN14 with YAP promotes the cytoplasmic sequestration of YAP from the nucleus in response to cell contact inhibition (87-89). More recently, Nemo-like kinase (NLK) regulates YAP localization and transcriptional activity in a cell-density dependent manner. At low cell density, NLK directly phosphorylates YAP at S128, which blocks LATS1/2-mediated phosphorylation at S127 and the 14-3-3 interaction. However, NLK is unable to activate YAP at a high cell density due to its cytoplasmic localization and degradation (90).

Many types of mechanical signals, including fluid shear stress, cell geometry and tensional force, have an effect on the complex architectures of organs and a growing body of evidence has placed YAP/TAZ as the critical mechanosensitive transducers that translate mechanical inputs into gene expression (91-93). These roles of YAP/TAZ in mechanotransduction are important in the physiological and pathological relevance to better understand related diseases, including atherosclerosis and cardiac hypertrophy, and mesenchymal stem cell differentiation (93). Physical alteration by ECM stiffness and cell shape regulates YAP/TAZ nuclear localization via the cytoskeleton rearrangement which is determined by Rho-GTPase, FAK-Src or LATS1/2 dependent pathways (94, 95). Recent report suggests that extracellular stiffness applied from the cytoskeleton into the nucleus can stretch the nuclear pore and consequently increase the nuclear entry of YAP (96).
Further details about the regulation of Hippo signaling by actin remodeling are reviewed in an accompanying paper (Seo and Kim, in this issue).

**Cellular stress**

Because YAP/TAZ are multifunctional transcription activators involved in a variety of cellular responses and a tight coordination between metabolism and the signaling pathway involved in cell proliferation is eventually required for organ growth, it has been expected that several stress signals such as nutrient starvation, energy stress and hypoxia may have effect on the Hippo signaling pathway (11, 97). The first link of YAP/TAZ to cellular metabolism emerged from the mevalonate pathway that has crucial roles in multiple cellular processes by synthesizing essential bioactive molecules such as cholesterol, bile acid and dolichol (98, 99). Pharmacological inhibitors of the mevalonate pathway efficiently block YAP/TAZ activity though RHO-GTPase (99). Serum or glucose deprivation rapidly induces LATS1/2 activation and subsequent YAP/TAZ inactivation for energy homeostasis. Moreover, the kinase AMPK, as a sensor of cellular energy stress, directly phosphorylates YAP at S94, which is a residue essential for the interaction with TEAD, to disrupt the interaction with TEAD (100, 101). Recent reports further provided interesting finding that YAP is O-GlcNAcylated by OGT in response to metabolic nutrients. YAP O-GlcNAcylation inhibits LATS1 mediated phosphorylation of YAP and represses YAP activity in tumorigenesis (102, 103).

Hypoxia represents a low level of oxygen at the tissue level and is a common feature in a majority of malignant tumors. HIF-1α functions as an oxygen sensor and is highly increased under hypoxia. Recent reports suggest that hypoxic stress deactivates the Hippo pathway via SIAH2-mediated LATS1/2 degradation. Augmented YAP interacts with HIF-1α which enhances YAP stabilization and function in tumors (104). Likewise, HIF-2α promotes cancer cell growth by inducing YAP expression and activity (105). In addition to YAP, HIF-1α can activate the WWTR gene that encodes the TAZ protein and serves as a co-activator (106). Further investigation provided details regarding the molecular mechanism for SIAH2-mediated LATS degradation under hypoxia. TGF-β signaling and expression of its target gene Zyxin are significantly elevated under hypoxia. As a result, Zyxin forms a functional ternary complex with LATS2 and SIAH2 and facilitates LATS2 degradation (107). Osmotic stress is recently reported to modulate the Hippo signaling; although, temporal duration exposed to osmotic stress differently affects YAP activity (108, 109). Acute osmotic stress promotes YAP nuclear localization and transcriptional activity by NLK-mediated phosphorylation (108). However, at later stages, osmotic stress promotes cytoplasmic translocation of TEAD via direct interaction with p38, which leads to the inhibition of YAP activity (109).

MST1/2 is originally isolated as a stress-responsive kinase activated by extreme stress, such as heat shock, okadaic acid or sodium arsenite (110), and mediates cellular responses to oxidative stress and longevity through the FOXO transcriptional factor (111). Recent work revealed that the YAP directly forms a functional complex with FOXO1 to activate the expression of antioxidant genes and consequently exert protective effects against oxidative stress and ischemia/ reperfusion (I/R)-caused injury in the heart (112). Further identification and functional analysis of new players that link stress and nutrients to Hippo signaling will provide potential therapeutic intervention points for treating cancer and metabolic diseases.

**HIPPO PATHWAY IS A HUB FOR INTEGRATION OF OTHER SIGNALING PATHWAYS**

Multiple signaling pathways converge and integrate with other pathways in tightly regulating numerous cellular responses, development and pathogenesis. In this review, we discuss the cross-talks between Hippo and other signaling pathways such as Wnt, Notch, GPCR and TGFβ pathways (Fig. 3).

**Wnt/β-catenin signaling pathway**

The Wnt/β-catenin pathway is known for its crucial role in embryonic development and tissue homeostasis in adults (113). In the absence of Wnt stimulation, a key transcriptional activator β-catenin is constantly degraded by a destruction complex that includes Axin, APC and GSK-3β, thereby maintaining a low level of β-catenin in the cytoplasm. Conversely, cytoplasmic β-catenin is accumulated in the presence of Wnt stimulation and enters the nucleus to activate the Wnt-responsive transcriptional program (113, 114). Multiple studies suggested that the Hippo pathway and Wnt/β-catenin signaling are integrated for the fine regulation of its own signaling in a physiological context. The first evidence for crosstalk between the Hippo and Wnt/β-catenin pathway was provided by Attisano and colleagues (115). The activation of the Hippo pathway increases the level of cytoplasmic TAZ to repress Wnt/β-catenin signaling by inhibiting CK1ε-mediated phosphorylation of Dishevelled (DVL). The Taz-KO mouse is known to develop a severe polycystic kidney (PKD) that is similar to the phenotype caused by aberrant Wnt/β-catenin signaling activation and it exhibits elevated transcriptional activity of β-catenin in kidney cysts. Interestingly, the levels of Armadillo, β-catenin homolog in Drosophila, and expression of its target genes are increased in the hpo and wts mutant clone of Drosophila (115). Similarly, YAP/TAZ physically binds and sequestrates β-catenin in the cytoplasm, thereby suppressing Wnt signaling (116). Furthermore, cytoplasmic YAP displayed a tumor suppressive function by restricting the nuclear translocation of DVL without modulating Axin/APC-GSK3β complex, and subsequently dampening Wnt signaling activation during intestinal regeneration (117). Alternatively, the Hippo pathway regulates the subcellular distribution of
SHP2 tyrosine phosphatase that is known to be a potent activator of Wnt/β-catenin signaling at the nucleus in a cell-density dependent manner. In high cell density, SHP2 is cytoplasmic via an interaction with phosphorylated YAP/TAZ, which suggests that the activation of Hippo signaling suppresses the Wnt signaling activity. Conversely, unphosphorylated YAP/TAZ promotes SHP2 nuclear localization and ultimately activates Wnt signaling in low cell density (118). Taken together, there are at least four different ways that the Hippo signaling inhibits Wnt/β-catenin signaling and the main mechanism is sequestration of the activators of Wnt/β-catenin signaling in the cytoplasm by interacting with cytoplasmic YAP/TAZ.

It is likely that the in vivo reciprocal relationship between Wnt/β-catenin and the Hippo pathway depends on the tissue context. Deletion of the Hippo components, Sav and Mst1/2, in neonatal heart displayed induced cardiomyocyte proliferation and cardiomegaly together with the elevated Wnt/β-catenin signaling signature (119). YAP and β-catenin forms a complex in the promoter of the progenitor genes, such as Sox2 and Snai2/Slug, and enhances gene expression. Heterozygotic removal of β-catenin in Sav/KO suppressed cardiomyocyte proliferation and heart overgrowth, which suggests that Wnt/β-catenin signaling is required for the phenotypes in Hippo mutants (119). Likewise, the ablation of the Hippo signaling by genetically deleting Mst1 and Mst2 (Mst1/2-DKO) resulted in the elevation of YAP/TAZ as well as β-catenin signaling activity. However, in contrast to its effect on the heart, additional loss of β-catenin in the Mst1/2-DKO mouse livers caused very severe hepatomegaly and accelerated tumor formation than those observed in Mst1/2-DKO (120). In line with this, the clinical investigation reveals that the YAP activation signature exhibits a negative correlation with β-catenin activation signature in patients with hepatocellular carcinoma (121). These reports suggest that YAP/TAZ can act as oncogene or tumor suppressor in a context dependent manner.

A large body of evidence has suggested that YAP/TAZ are intrinsic regulators of Wnt signal transduction and orchestrates Wnt-mediated biological responses. Similar to the β-catenin regulation, YAP and TAZ were integral components and sequeestrated by the β-catenin destruction complex in the cytoplasm. β-catenin mediates TAZ, but not YAP, degradation in the absence of Wnt. YAP/TAZ also inhibit β-catenin activity via the recruitment of β-TrCP into the destruction complex. However, in the presence of Wnt, YAP and TAZ are released from the destruction complex and enter into the nucleus to enhance target gene expression (122, 123). These provocative findings suggest that the expression of Wnt target genes is regulated by the well-known β-catenin-TCF/LEF as well as YAP/TAZ-TEAD complexes. However, Pan and colleagues demonstrated that YAP is not regulated by the β-catenin destruction complex, but rather the APC protein complex that facilitates the phosphorylation of YAP/TAZ through the Hippo kinase cascade (124). It is not clear whether this discrepancy is due to difference in the cellular context. Further work is required to resolve this discrepancy.

**G-protein-coupled receptors (GPCRs)**

G-protein-coupled receptors (GPCRs) contain seven transmembrane domains and are the largest family of the plasma membrane receptors that mediate signals from the outside to the inside of the cell. A major conceptual advance was the identification of GPCRs as a bona fide upstream regulator of the Hippo signaling pathway (125). GPCR signaling differentially regulates the Hippo pathway, which depends on the types of heterotrimeric G-protein that are induced by the different ligands. Guan and colleagues examined the effect of serum on YAP/TAZ phosphorylation and activation to search for upstream regulators of the Hippo pathway. Serum induces the dephosphorylation and nuclear translocation of YAP, and further investigation identified bioactive phospholipids in serum, such as lyso phosphatidic acid (LPA) or sphingosine 1-phosphate (S1P), as the YAP/TAZ activating components. LPA or S1P treatment was sufficient to promote YAP/TAZ activation through G12/13-coupled receptor signaling. Further investigation indicated GPCRs that activate G12/13, Gq/11 and Gs signaling inhibit YAP/TAZ phosphorylation and degradation. In particular, the YAP/TAZ regulation by GPCR is closely associated with a variety of cancers. For example, Gq/11-active mutation is observed in approximately 80% of uveal melanoma where YAP has the essential role in tumorigenesis. Mechanistically, these GPCRs inhibit LATS1/2 activity through Rho-GTPase, thereby inducing YAP/TAZ dephosphorylation and nuclear localization. In contrast, ephinephrine, glucagon or dopamine that activates Gs-coupled receptor elevated LATS1/2 kinase activity through protein kinase A and consequently inhibits YAP/TAZ activity. LATS1/2 served as the key downstream mediators in the regulation of YAP/TAZ by GPCRs; but, it remains controversial since Miller et al. demonstrated that LATS1/2 was not involved in S1P-mediated YAP dephosphorylation (126). Frizzled (Fz) is a primary receptor for Wnt ligands and belongs to the GPCR family. A recent study reported that the noncanonical Wnt ligands, such as Wnt5a/b, activate YAP/TAZ via Fz-G12/13-RhoGTPase-LATS1/2 signaling axis that is independent from the canonical Wnt/β-catenin pathway (127). It would be of importance to identify more GPCRs which transduce the extracellular signal to the Hippo signaling pathway in different cellular contexts, since these GPCRs can be used as specific therapeutic targets by using currently available agonists or antagonists.

**Notch signaling pathway**

Notch signaling functions in diverse developmental and homeostatic processes and is activated by cell-cell contact that induce the direct interaction between the Notch receptors and their cognate ligands (Jagged and Delta-like). These bindings
induce sequential proteolytic cleavage of the Notch receptor and ultimately generate the Notch intracellular domain (NICD) to activate the expression of target genes (128-130). Although the Hippo pathway was initially reported to be involved in the Notch-dependent differentiation in Drosophila (131, 132), a direct link between the two signaling pathways was extensively studied in mammalian development and tissue homeostasis. Genetic manipulation revealed that YAP was required for intestinal expansion, smooth muscle differentiation and controlling liver cell fate via the up-regulation of the Notch signaling (133-136). During embryonic development, the Notch pathway is activated in the trophoectoderm (TE), which give rise to the placenta, where NICD and YAP cooperatively activate Chd2 transcription for TE lineage specification (137). A series of studies provided the mechanistic insight that Notch receptors and its ligand Jagged1 were direct target genes of YAP and NICD enhanced YAP/TAZ activity by at least promoting stabilization, which creates a positive feedback loop during tumorigenesis (120, 134, 138).

**TGF-β signaling**

The transforming growth factor-β (TGF-β) superfamily participates in the regulation of numerous biological processes, including cell growth, organogenesis and stem cell function (139). The TGFβ ligands bind to their specific Ser/Thr kinase receptors to induce the activation of SMAD transcription factors and its target gene expression. Recent studies have unveiled a cooperative interaction between the Hippo and TGF-β-SMAD signaling in many cellular responses (140-142). In human embryonic stem cells (hESC), the Hippo pathway cooperates with the TGFβ signaling to maintain pluripotency (143). Upon TGFβ stimulation, TAZ physically binds and promotes SMAD2/3 nuclear localization to induce the transcription of genes that are involved in the maintenance of hESC pluripotency (143). Conversely, in response to cell density, the Hippo pathway suppresses the TGFβ signaling via YAP/TAZ-mediated SMAD cytoplasmic sequestration (80). However, YAP/TAZ-dependent SMAD localization needs to be further clarified since the controversial result was reported that the TGFβ signaling and SMAD nuclear localization was not affected by cell density in most cell types (144). In addition to its role in embryonic stem cells, YAP controls patterning of the developing lung and induces specific transcriptional programs to generate airways (145, 146). YAP also induces the differentiation of hepatoblasts into biliary epithelial cells by cooperating with the TGFβ signaling (147). YAP/TAZ and TGFβ signaling can form a positive feedback loop in tumorigenesis. TGFβ ligands, including BMP and TGFβ2/3, can be transcriptionally induced by the inactivation of the Hippo pathway (148, 149). A specific loss of Mob1a/b, which is a negative regulator of YAP/TAZ, in the liver results in the increase of Tgfβ2/3 expression. Indeed, the genetic ablation of the Tgfβ receptor (Tgfrb2) in Mob1a/b-deficient mice livers partially alleviated liver enlargement, fibrosis and tumori-offspring (149).

Multiple molecular layers between the Hippo pathway and TGFβ signaling have been reported. The Hippo pathway scaffold RASFF1A was degraded by the ITCH E3 ligase mediated proteosome pathway in response to TGFβ signaling, thereby permitting the YAP-SMAD2 complex formation and nuclear localization for transcriptional activation of the TGFβ-responsive targets (150). SnoN, which is a target gene of TGFβ signaling and maintains the repressed state of TGFβ-responsive targets in the absence of ligands as a negative feedback mechanism (151), promotes TAZ stabilization via the inhibition of LATS-mediated phosphorylation and is required for oncogenic function of TAZ (147). Interestingly, the expression and localization of SnoN can be regulated by cell density-dependent Hippo pathway activation (152). Overall, these reports clearly suggest that there are extensive cross-talks between the components of the Hippo and TGFβ signaling, and thus we need to be aware that modulation of one signaling may have elicit unexpected effects by regulating any other signaling.

**CONCLUDING REMARKS**

Owing to vast efforts of many researchers, the Hippo pathway has been firmly established as a master regulator of organ size control. Also, the molecular mechanism of the Hippo pathway that transduces from the extracellular stimuli to transcription has been well elucidated. Apart from its primary functions in organ size determination, development and tumor suppression, recent studies revealed the unexpected roles of Hippo signaling in diverse cellular processes such as angiogenesis (Park and Kwon, in this issue), miRNA biogenesis, regulation of innate immunity and mechanotransduction. Given these various cellular functions, it is not surprising that the Hippo pathway senses multiple stimuli and translates it to intracellular responses by cooperating with other signaling pathways. Despite the rapid and extensive progress in the Hippo pathway, further provocative findings are expected in coming years to answer fundamental questions in this field and to provide clinical insights for curing human diseases.

**ACKNOWLEDGEMENTS**

We sincerely apologize to researchers whose work was not cited in this review due to space limitations. This work was supported by the grants from the KRIBB Initiative of the Korea Research Council of Fundamental Science and Technology to W. Kim and the National Research Foundation of Korea (NRF-2016R1E1A1A01943544 and NRF-2017M3A9B4062421) to E. Jho.

**CONFLICTS OF INTEREST**

The authors have no conflicting interests.
REFERENCES

1. Shingleton AW (2010) The regulation of organ size in Drosophila: physiology, plasticity, patterning and physical force. Organogenesis 6, 76-87
2. Gokhale RH and Shingleton AW (2015) Size control: the developmental physiology of body and organ size regulation. Wiley Interdiscip Rev Dev Biol 4, 335-356
3. Halder G and Johnson RL (2011) Hippo signaling: growth control and beyond. Development 138, 9-22
4. Twitty VCS, Josep L (1931) The growth of eyes and limbs transplanted heteroplastically between two species of Amblystoma. J Exp Zool 39, 61-86
5. Michalopoulos GK and DeFrances MC (1997) Liver regeneration. Science 276, 60-66
6. Metcalf D (1964) Restricted Growth Capacity of Multiple Spleen Transplants. Transplantation 2, 387-392
7. Metcalf D (1963) The Autonomous Behaviour of Normal Thymus Transplants. Aust J Exp Biol Med Sci 41, SUPPL43-447
8. Hilman D and Gat U (2011) The evolutionary history of Yap and the hippoYAP pathway. Mol Biol Ecol 28, 2403-2417
9. Sebe-Pedros A, Zheng Y, Ruiz-Trillo I and Pan D (2012) Premetazoan origin of the hippo signaling pathway. Cell Rep 1, 13-20
10. Huang J, Wu S, Barrera J, Matthews K and Pan D (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122, 421-434
11. Meng Z, Moroishi T and Guan KL (2016) Mechanisms of Hippo pathway regulation. Genes Dev 30, 1-17
12. Piccolo S, Dupont S and Cordenonsi M (2014) The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 94, 1287-1312
13. Zhao B, Li L, Tumaneng K, Wang CY and Guan KL (2010) A coordinated phosphorylation by Lats and CK1 regulates Yap stability through SCF(beta-TRCP). Genes Dev 24, 72-85
14. Liu CY, Zha ZY, Zhou X et al (2010) The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF[beta]-TrCP E3 ligase. J Biol Chem 285, 37159-37169
15. Huang W, Lv X, Liu C et al (2012) The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFbeta-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. J Biol Chem 287, 26245-26253
16. Hansen CG, Moroishi T and Guan KL (2015) YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol 25, 499-513
17. Meng Z, Moroishi T, Mottier-Pavie V et al (2015) MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat Commun 6, 8357
18. Kim Y, Kim W, Song Y et al (2017) Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability. Proc Natl Acad Sci U S A 114, 4691-4696
19. Yin F, Yu J, Zheng Y, Chen Q, Zhang N and Pan D (2013) Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 154, 1342-1355
20. Fulford A, Tapon N and Ribeiro PS (2017) Upstairs, downstairs: spatial regulation of Hippo signalling. Curr Opin Cell Biol 51, 22-32
21. Chaulk SG, Lattanzi VJ, Hiemer SE, Fahleman RP and Varelas X (2014) The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7. J Biol Chem 289, 1886-1891
22. Mori M, Trbovec R, Mohseni M et al (2014) Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell 156, 893-906
23. Sabine A, Boxay E, Demir CS et al (2015) FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature. J Clin Invest 125, 3861-3877
24. Wang L, Luo JY, Li B et al (2016) Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow. Nature 540, 579-582
25. Liu B, Zheng Y, Yin F, Yu J, Silverman N and Pan D (2016) Toll Receptor-Mediated Hippo Signaling Controls Innate Immunity in Drosophila. Cell 164, 406-419
26. Wang S, Xie F, Chu F et al (2017) YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKvarepsilon-mediated phosphorylation. Nat Immunol 18, 733-743
27. Wilkinson DS, Jariwala JS, Anderson E et al (2015) Phosphorylation of LC3 by the Hippo kinases STK3/SYK4 is essential for autophagy. Mol Cell 57, 55-68
28. Maejima Y, Kyo S, Zhai P et al (2013) Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat Med 19, 1478-1488
29. Zhang S, Chen Q, Liu Q et al (2017) Hippo Signaling Suppresses Cell Ploidy and Tumorigenesis through Skp2. Cancer Cell 31, 669-684 e7
30. Justice RW, Zilian O, Woods DF, Noll M and Bryant PJ (1995) The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev 9, 534-546
31. Xu T, Wang W, Zhang S, Stewart RA and Yu W (1995) Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 121, 1053-1063
32. St John MA, Tao W, Fei X et al (1999) Mice deficient of a Drosophila homologue of human myotonic dystrophy kinase develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 21, 182-186
33. Tao W, Zhang S, Turenchalk GS et al (1999) Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat Genet 21, 177-181
34. Tapon N, Harvey KF, Bell DW et al (2002) salvador phosphatidylinositol 3-kinase inhibition. J Biol Chem 287, 37159-37169
35. Varelas X (2014) The Hippo pathway effectors TAZ/YAP antagonize Drosophila: Physiology, plasticity, patterning and physical force. Organogenesis 6, 76-87
Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 114, 457-467

37. Udan RS, Kango-Singh M, Nolo R, Tao C and Halder G (2003) Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol 5, 914-920

38. Pantalacci S, Tapon N and Leopold P (2003) The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol 5, 921-927

39. Iia J, Zhang W, Wang B, Trinko R and Jiang J (2003) The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev 17, 2514-2519

40. Wu S, Huang J, Dong J and Pan D (2003) hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with Salvador and warts. Cell 114, 445-456

41. Lai ZC, Wei X, Shimizu T et al (2005) Control of cell proliferation and apoptosis by mob as tumor suppressor, mts. Cell 120, 675-685

42. Wei X, Shimizu T and Lai ZC (2007) Mob as tumor suppressor is activated by Hippo kinase for growth inhibition in Drosophila. EMBO J 26, 1772-1781

43. Zhao B, Wei X, Li W et al (2007) Inactivation of YAP oncprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21, 2747-2761

44. Zhang N, Bai H, David KK et al (2010) The Merlin/NF2 tumor suppressor functions through the YAP oncprotein to regulate tissue homeostasis in mammals. Dev Cell 19, 27-38

45. Overholtzer M, Zhang J, Smolen GA et al (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 103, 12405-12410

46. Harvey KF, Zhang X and Thomas DM (2013) The Hippo pathway and human cancer. Nat Rev Cancer 13, 246-257

47. Johnson R and Halder G (2014) The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 13, 63-79

48. Mороish T, Hansen CG and Guan KL (2015) The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 15, 73-79

49. Sudol M (1994) Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9, 2145-2152

50. Komuro A, Nagai M, Navin NE and Sudol M (2003) WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278, 33334-33341

51. Ferrigno O, Lallemand F, Verrecchia F et al (2002) Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling. Oncogene 21, 4879-4884

52. Strano S, Munarriz E, Rossi M et al (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276, 15164-15173

53. Zaidi SK, Sullivan AJ, Medina R et al (2004) Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 23, 790-799

54. Vassilev A, Kaneko KJ, Shu H, Zhao Y and DePamphilis ML (2001) TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 15, 1229-1241

55. Yagi R, Chen LF, Shigesada K, Murakami Y and Ito Y (1999) A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 18, 2531-2562

56. Espanel X and Sudol M (2001) Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem 276, 14514-14523

57. Osu M and Sasaki H (2008) Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Development 135, 4059-4069

58. Wu S, Liu Y, Zheng Y, Dong J and Pan D (2008) The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell 14, 388-398

59. Zhang L, Ren F, Zhang Q, Chen Y, Wang B and Jiang J (2008) The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Dev Cell 14, 377-387

60. Zhao B, Ye X, Yu J et al (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22, 1962-1971

61. Schlegelmilch K, Molsen M, Kirak O et al (2011) Rap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 144, 782-795

62. von Gise A, Lin Z, Schlegelmilch K et al (2012) YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc Natl Acad Sci U S A 109, 2394-2399

63. Zhang W, Gao Y, Li P et al (2014) VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res 24, 331-343

64. Koontz LM, Liu-Chittenden Y, Yin F et al (2013) The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev Cell 25, 388-401

65. Hamaratogluglu F, Willecke M, Kango-Singh M et al (2006) The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 8, 27-36

66. Willecke M, Hamaratogluglu F, Kango-Singh M et al (2006) The cadherin acts through the Hippo tumor-suppressor pathway to regulate tissue size. Curr Biol 16, 2090-2100

67. Silva E, Tsatskis Y, Gardano L, Tapon N and McNeill H (2006) The TESR family member TESR1 antagonizes scalloped-mediated default repression. Dev Cell 14, 388-398

68. Cho E, Feng Y, Rauskolb C, Maitra S, Fehon R and Irvine KD (2006) Identification of a Fat tumor suppressor pathway. Nat Genet 38, 1142-1150

69. Vassilev A, Kaneko KJ, Shu H, Zhao Y and DePamphilis ML (2001) TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 15, 1229-1241
Wantae Kim and Eek-hoon Jho

Overview of the Hippo signaling pathway

Wantae Kim and Eek-hoon Jho

69. Poon CL, Lin Jl, Zhang X and Harvey KF (2011) The sterile 20-like kinase Tao-1 controls tissue growth by regulating the Salvador-Warts-Hippo pathway. Dev Cell 21, 896-906

70. Boggiano JC, Vanderzalm PJ and Fehon RG (2011) Tao-1 phosphorylates Hippo/MST kinases to regulate the Hippo-Salvador-Warts tumor suppressor pathway. Dev Cell 21, 888-895

71. Chung HL, Augustine GJ and Choi KW (2016) Drosophila Schip1 Links Expanded and Tao-1 to Regulate Hippo Signaling. Dev Cell 36, 511-524

72. Yu J, Zheng Y, Dong J, Klusza S, Deng WM and Pan D (2010) Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell 18, 288-299

73. Genevet A, Wehr MC, Brain R, Thompson BJ and Tapon N (2010) Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell 18, 300-308

74. Baumgartner R, Poembacher I, Buser N, Hafen E and Stocker H (2010) The WW domain protein Kibra acts upstream of Hippo in Drosophila. Dev Cell 18, 309-316

75. Su T, Ludwig MZ, Xu J and Fehon RG (2017) Kibra and Merlin Activate the Hippo Pathway Spatially Distinct from and Independent of Expanded. Dev Cell 40, 478-490 e473

76. Thompson BJ, Pichaud F and Roper K (2013) Sticking together the Crumbs - an unexpected function for an old friend. Nat Rev Mol Cell Biol 14, 307-314

77. Chen CL, Gajewski KM, Hamaratoglu F et al (2010) The apical-basal cell polarity determinant Crumbs regulates Hippo signaling in Drosophila. Proc Natl Acad Sci U S A 107, 15810-15815

78. Ling C, Zheng Y, Yin F et al (2010) The apical transmembrane protein Crumbs functions as a tumor suppressor that regulates Hippo signaling by binding to Expanded. Proc Natl Acad Sci U S A 107, 10532-10537

79. Grzeschik NA, Parsons LM, Allott ML, Harvey KF and Richardson HE (2010) Lgl, apKC, and Crumbs regulate the Salvador/Warts/Hippo pathway through two distinct mechanisms. Curr Biol 20, 573-581

80. Varelas X, Samavarchi-Tehrani P, Narimatsu M et al (2010) The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-Smad pathway. Dev Cell 19, 831-844

81. Hirano S, Kimoto N, Shimoyama Y, Hirohashi S and Takeichi M (1992) Identification of a neural alpha-catenin as a key regulator of cadherin function and multicellular organization. Cell 70, 293-301

82. Herrenknecht K, Ozawa M, Eckerskorn C, Lottspeich F, Lenter M and Kemler R (1991) The uvomorulin-anchorage protein alpha catenin is a vinculin homologue. Proc Natl Acad Sci U S A 88, 9156-9160

83. Silvis MR, Kreger BT, Lien WH et al (2011) alpha-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. Sci Signal 4, r33

84. Wei SY, Escudero LM, Yu F et al (2005) Echinoid is a component of adherens junctions that cooperates with DE-Cadherin to mediate cell adhesion. Dev Cell 8, 493-504

85. Yue T, Tian A and Jiang J (2012) The cell adhesion molecule echinoid functions as a tumor suppressor and upstream regulator of the Hippo signaling pathway. Dev Cell 22, 253-267

86. Nishioka N, Inoue K, Adachi K et al (2009) The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev Cell 16, 398-410

87. Wang W, Huang J, Wang X et al (2012) PTPN14 is required for the density-dependent control of YAP1. Genes Dev 26, 1959-1971

88. Liu X, Yang N, Fiegel SA et al (2013) PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene 32, 1266-1273

89. Michaloglou C, Lehrmann W, Martin T et al (2013) The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. PLoS One 8, e61916

90. Moon S, Kim W, Kim S et al (2017) Phosphorylation by NLK inhibits YAP-14-3-3-interactions and induces its nuclear localization. EMBO Rep 18, 61-71

91. Dupont S, Morsat L, Aragona M et al (2011) Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183

92. Halder G, Dupont S and Piccolo S (2012) Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol 13, 591-600

93. Panciera T, Azzolin L, Cordenonsi M and Piccolo S (2017) Mechanobiology of YAP and TAZ in physiology and disease. Nat Rev Mol Cell Biol 12, 758-770

94. Zhao B, Li L, Wang L, Wang CY, Yu J and Guan KL (2011) Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 25, 54-68

95. Kim NG and Gumbiner BM (2015) Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway. J Cell Biol 210, 503-515

96. Elsegui-Artola A, Andreu I, Beedle AEM et al (2017) Force Triggers YAP Nuclear Entry by Regulating Transport across Nuclear Pores. Cell 171, 1397-1410

97. Mo JS (2017) The role of extracellular biophysical cues in modulating the Hippo-YAP pathway. BMB Rep 50, 71-78

98. Wang Z, Wu Y, Wang H et al (2014) Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A 111, EB9-98

99. Somrentino G, Ruggeri N, Specchia V et al (2014) Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 16, 357-366

100. Mo JS, Meng Z, Kim YC et al (2015) Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat Cell Biol 17, 500-510

101. Wang W, Xiao ZD, Li X et al (2015) AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat Cell Biol 17, 490-499

102. Zhang X, Qiao Y, Wu Q et al (2017) The essential role of Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation. Nat Commun 8, 15280

103. Peng C, Zhu Y, Zhang W et al (2017) Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation. Mol Cell 68, 591-604 e595

116
Overview of the Hippo signaling pathway
Wantae Kim and Eek-hoon Jho

Perspect Biol 9, a022137

141. Ayyaz A, Attisano L and Wrana JL (2017) Recent advances in understanding contextual TGFbeta signaling. F1000Res 6, 749

142. Attisano L and Wrana JL (2013) Signal integration in TGF-beta, WNT, and Hippo pathways. F1000Prime Rep 5, 17

143. Varelas X, Sakuma R, Samavarchi-Tehrani P et al (2008) TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 10, 837-848

144. Nallet-Staub F, Yin X, Gilbert C et al (2015) Cell density sensing alters TGF-beta signaling in a cell-type-specific manner, independent from Hippo pathway activation. Dev Cell 32, 640-651

145. Mahoney JE, Mori M, Szymaniak AD, Varelas X and Cardoso WV (2014) The hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitors. Dev Cell 30, 137-150

146. Zhao R, Fallon TR, Saladi SV et al (2014) Yap tunes airway epithelial size and architecture by regulating the identity, maintenance, and self-renewal of stem cells. Dev Cell 30, 151-165

147. Lee DH, Park JO, Kim TS et al (2016) LATS-YAP/TAZ controls lineage specification by regulating TGFbeta signaling and Hnf4alpha expression during liver development. Nat Commun 7, 11961

148. Lai D and Yang X (2013) BMP4 is a novel transcriptional target and mediator of mammary cell migration downstream of the Hippo pathway component TAZ. Cell Signal 25, 1720-1728

149. Nishio M, Sugimachi K, Goto H et al (2016) Dysregulated YAP1/TAZ and TGF-beta signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. Proc Natl Acad Sci U S A 113, E71-80

150. Pefani DE, Pankova D, Abraham AG et al (2016) TGF-beta Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation. Mol Cell 63, 156-166

151. Stroschein SL, Wang W, Zhou S, Zhou Q and Luo K (1999) Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 286, 771-774

152. Zhu Q, Le Scolan E, Jahchan N, Ji X, Xu A and Luo K (2016) SnoN Antagonizes the Hippo Kinase Complex to Promote TAZ Signaling during Breast Carcinogenesis. Dev Cell 37, 399-412